Iron and cancer: more ore to be mined

By Suzy V. Torti, Frank M. Torti. Nature Reviews. Cancer, 2013

1,479 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/94f863f23b442ed5bfa65466bcfed38a38c30d56

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

In Molecular Biology

Citations in the corpus

HSPB1 as a Novel Regulator of Ferroptotic Cancer Cell Death (2015, background): “Thus, when cancer cells contain aberrantly elevated levels of iron and HSPB1 (37, 38), the cells may be predisposed to ferroptotic cell death if the HSPB1 pathway is down-regulated.”
The Roles of NRF2 in Modulating Cellular Iron Homeostasis (2017, background): “Given that iron is an essential nutrient and iron-containing proteins play diverse roles in cell cycle, DNA repair, and metabolism, many proteins involved in modulating iron homeostasis are now implicated in cancer, including the aforementioned ferroportin and ferritin proteins (92, 154).”
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies (2024, background): “11,368,369 Intriguingly, mesenchymal and dedifferentiated cancer cells, which are usually resistant to apoptosis and traditional therapies, are exquisitely vulnerable to ferropto-sis.”
The Development of the Concept of Ferroptosis (2018, neutral): “The ironenriched (ferroptosis-promoting) tumor environment [220], along with”
Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease (2015, background): “Iron has long been associated with cell proliferation and tumorigenesis, and cancer cells are known to stockpile intracellular iron through dysregulation of iron metabolism, in part by upregulating genes involved in iron uptake (reviewed in [54]).”
The Tumor Suppressor Protein p53 and the Ferroptosis Network (2018, neutral): “Excess iron can be a risk for carcinogenesis and neurodegenerative diseases [79,80].”
Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, positive): “Several iron chelators are being evaluated as anti-cancer agents [143].”